Retension Pharmaceuticals Appoints Alison Schecter as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
Position
Chief Financial Officer
Company
Retension Pharmaceuticals
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Retension Pharmaceuticals has announced the appointments of Alison D. Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer. These seasoned executives bring extensive clinical development and financial expertise to the company as it advances RTN-001 through its Phase 2b clinical trial.
Quick answer
Retension Pharmaceuticals Appoints Alison Schecter as Chief Medical Officer and Alex Schwartz as Chief Financial Officer (May 27, 2026). Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- Who is the new Chief Financial Officer at Retension Pharmaceuticals?
- Retension Pharmaceuticals named Alex Schwartz Chief Financial Officer, announced May 27, 2026.
- What did Retension Pharmaceuticals announce on May 27, 2026?
- Retension Pharmaceuticals has announced the appointments of Alison D. Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer. These seasoned executives bring extensive clinical development and financial expertise to the company as it advances RTN-001 through its Phase 2b clinical trial.
- What does Retension Pharmaceuticals do?
- Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension.
- Where is Retension Pharmaceuticals based?
- Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- Which similar companies made leadership changes around the same time?
- VistaGen (May 20, 2026), OnCusp Therapeutics (May 14, 2026), Poxel (June 10, 2026) and TORL BioTherapeutics (May 7, 2026) also announced leadership changes within 45 days of Retension Pharmaceuticals.
Source: Fundz verified event record.
Other recent leadership changes in Healthcare and Therapeutics
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- VistaGen Therapeutics Appoints Angel S. Angelov as Chief Medical Officer (May 20, 2026)
- OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer (May 14, 2026)
- Poxel Appoints Yves Decadt as Chief Executive Officer (June 10, 2026)
- TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer (May 7, 2026)
- Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager of Saudi Arabia and Gulf Countries (June 17, 2026)
- BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran as CEO and Idan Elmelech as COO (April 22, 2026)
Who to call at Retension Pharmaceuticals, and when
A new leader at Retension Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Retension Pharmaceuticals changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.